BRISTOL-MYERS SQUIBB COMPANY for BRISTOL-MYERS SQUIBB COMPANY
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS BRUNET | — |
| JOHN DEOUDES | — |
| STEPHANIE A. DYSON | — |
| JEFFREY LAST | — |
| KATHRYN NOVARIA | — |
| LANE PENRY | — |
| RICARDO SANCHEZ ORTEGON | — |
| PAUL ANTHONY WILLIAMS | — |
Medicare/Medicaid MMM
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions Issues related to the Inflation Reduction Act of 2022 IRA implementation
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEPHANIE A. DYSON | — |
| LANE PENRY | — |
| RICARDO SANCHEZ ORTEGON | — |
| CAROLINE TUCKER | — |
| PAUL ANTHONY WILLIAMS | — |
Trade (domestic/foreign) TRD
Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICARDO SANCHEZ ORTEGON | — |
| PAUL ANTHONY WILLIAMS | — |
Taxation/Internal Revenue Code TAX
Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN DEOUDES | — |
Copyright/Patent/Trademark CPT
Intellectual Property Reform concerning bio-pharmaceutical industry
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEFFREY LAST | — |
| LANE PENRY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.